Multibagger Stock Alert! Shares Hit 5% Upper Circuit After Positive Q2 Results

On Friday, shares of pharma company Evexia Lifecare Ltd jumped around 7.25 per cent to an intraday high of Rs 4.40 per share from its previous closing of Rs 4.07 per share. The stock's 52-week high is Rs 4.40 and its 52-week low is Rs 1.55. The company has a market cap of over Rs 816.64 crore with multibagger returns of 164 per cent in 1 year.

Evexia Lifecare's net profit increased 245.00% to Rs 0.69 crore in the September 2024 quarter from Rs 0.20 crore in the September 2023 quarter. In the quarter that concluded in September 2024, sales increased by 154.87% to Rs 26.71 crore, up from Rs 10.48 crore in the quarter that ended in September 2023.

Evexia Lifecare Limited recently stated a great milestone in efforts to expand its operations and focus by Issuing 24 crore Convertible Warrants on a select basis. This follows approval from the shareholders as per the Extraordinary General Meeting convened on October 23, 2024 and in principle approval from the Bombay Stock Exchange on October 29, 2024. Each warrant has been issued at a price of Rupees 3.60 with this allotment causing no change to the paid-up share capital of the company.

Pursuant to its thrust on increasing its presence within the pharmaceutical sector, Evexia Lifecare reached an agreement for a draft investment contract with DIPOned Research International Private Limited in which Evexia intends to acquire a 65 percent equity holding. The equity investment shall be made through the issuing of shares on preferential terms and quasi-capital, bolstering Evexia's diversification strategy and penetration into newer markets. As a modern contracting organization that provides drug discovery, development and contract research services, diponed offers good prospects for Evexia's expansion in the pharmaceutical and healthcare industry. The acquisition is expected to be finalized in the next 60 days subject to the satisfaction of certain conditions.

The shares of Evexia have again shown good development with investors increasing their stake in the company's shares with the stock rising by approximately 3.5 per cent to Rupees 4.02 on Thursday reaching an intraday of Rupees 4.23.

The stock has shown great progress such as 171.6 percent growth from its 52-week low of share price at Rs 1.55 which indicates an uptick for the company within the FMCG sector. At present, Evexia Lifecare has a market valuation of Rs 740 crore due to the positive quarterly and yearly reports.

Evexia has now expanded both its domestic and international marketing along with the recently acquired companies. Earlier, Evexia also made an entry into the UAE healthcare market by holding a 51 per cent interest in a new SPV owning 10 medical centres in UAE. This investment of Rs 190 crore allows doors for Evexia to broaden its medical practices in the emerging healthcare region. Evexia has also expressed its intentions to buy 51 per cent of Vittal's MediCare, a diagnostic centre based in India, furthering its penetration in the diagnostics industry and investigating possible synergies with its other business activities.

Evexia Lifecare has a profile that once existed as Kavit Industries Limited which emphasizes strength in chemical and agricultural commodities as well as consumer goods. The company has recently started a new subsidiary that seeks to open up pathology laboratories in Africa; a move which has opened the company's penetration in the continent's healthcare market.

Evidently, Evexia Lifecare has continued on its aggressive growth path both through internal growth and acquisitions.

Such measures would strengthen the company's image in the market, expand its means of earning, and create long-term goals for shareholders further consolidating Evexia as a major participant in pharmaceutical and healthcare.